Biomarkers of ICC, such as serum CA19-9 and CEA, have significant overlap in their concentrations with other, benign diseases, so their sensitivity and accuracy are far from satisfactory. The gene discussed is CEACAM5; the disease is intrahepatic cholangiocarcinoma.